Scleroderma Renal Crisis: A Pathology Perspective by Batal, Ibrahim et al.
Hindawi Publishing Corporation
International Journal of Rheumatology
Volume 2010, Article ID 543704, 7 pages
doi:10.1155/2010/543704
Review Article
SclerodermaRenal Crisis: A Pathology Perspective
Ibrahim Batal,1 Robyn T. Domsic,2 Thomas A. Medsger Jr.,2 andSheldon Bastacky1
1Department of Pathology, University of Pittsburgh Medical Center, A614 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15213, USA
2Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, 3500 Terrace Street,
BST, S7, Pittsburgh, PA 15261, USA
Correspondence should be addressed to Ibrahim Batal, ibrahim batal@yahoo.com
Received 14 May 2010; Accepted 28 June 2010
Academic Editor: Lorinda Chung
Copyright © 2010 Ibrahim Batal et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Scleroderma renal crisis (SRC) is an infrequent but serious complication of systemic sclerosis (SSc). It is associated with increased
vascular permeability, activation of coagulation cascade, and renin secretion, which may lead to the acute renal failure typically
associated with accelerated hypertension. The histologic picture of SRC is that of a thrombotic microangiopathy process with
prominent small vessel involvement manifesting as myxoid intimal changes, thrombi, onion skin lesions, and/or ﬁbrointimal
sclerosis. Renal biopsies play an important role in conﬁrming the clinical diagnosis, excluding overlapping/superimposed diseases
that might lead to acute renal failure in SSc patients, helping to predict the clinical outcome and optimizing patient management.
Kidney transplantation may be the only treatment option available for a subset of SRC patients who develop end-stage renal
failure despite aggressive angiotensin-converting enzyme inhibitor therapy. However, the posttransplant outcome for SSc patients
is currently suboptimal compared to the general renal transplant population.
1.Introduction
Systemic sclerosis (SSc) is a multisystem autoimmune dis-
order that can manifest as either the diﬀuse cutaneous
(dc) or the limited cutaneous (lc) variant, distinguished
by the degree and the extent of cutaneous sclerosis [1].
Scleroderma renal crisis (SRC) can complicate the course of
up to 10% of patients with SSc. Although most frequently
seen in dcSSc, SRC can occur in patients with lcSSc
[2, 3] and rarely in patients with no signiﬁcant dermal
sclerosis termed systemic sclerosis sine scleroderma (ssSSc)
[4]. The etiology of SCR remains incompletely understood,
with most models of pathogenesis suggesting an initial
trigger of vascular endothelial injury. Alteration in cellular
and/or humoral immunity may also play a role in SRC
pathogenesis [1, 5, 6]. SSc has been associated with T helper
lymphocyte type-2 (TH-2) activation, cytokine production
(particularly Il-4, IL-13, and IL-17), and excess collagen
accumulation, which could participate in the development
of vasculopathy [7]. B cell activation has also been described
in SSc patients [7]. The association between the presence
of several speciﬁc autoantibodies and the development of
SRC raises a potential contributing role of autoantibodies in
the pathogenesis of SRC [8, 9]. In addition, antiendothelial
cell antibodies, which are capable of inducing endothelial
cell apoptosis [10] have been detected in up to 85% of SSc
patients [11]. Overexpression of endothelin-1, a protein that
plays a role in blood vessel constriction, and its receptor
endothelin-B has been demonstrated in the small vessels of
two SRC patients [12]. Furthermore, the C4d complement
degradation product product is regarded as an immunologic
marker of antibody-mediated rejection in renal allografts,
has been detected in native renal biopsies from a subset of
SRC patients [13].
Subsequent to the potential endothelial triggering injury,
the proposed cascade of histologic alterations is initiated
by rapid increase in endothelial permeability and intimal
edema. This then places the subendothelial connective
tissue in direct contact with circulating blood elements
activating the coagulation cascade and vascular thrombosis.
The underlying connective tissue reacts to this insult by
promotingﬁbroblasticandnonﬁbroblasticstromalprolifera-
tion, which manifests as proliferative endarteropathy (onion
skin type lesion). Decreased renal perfusion as a result of
arterial narrowing can additionally lead to juxtaglomerular
apparatus (JGA) hyperplasia and renin secretion, resulting2 International Journal of Rheumatology
in accelerated hypertension and progressive renal injury. A
milder form of vascular pathology, manifested usually as
ﬁbrointimal thickening can often be observed in SSc patients
without SRC [14].
Adequate renal biopsy specimens are generally capable
of reﬂecting the aforementioned pathophysiologic changes.
A detailed histologic assessment can conﬁrm the clinical
diagnosis and help exclude potential overlapping or super-
imposed etiologies.
2. Clinicaland LaboratoryFeatures
SRC is typically characterized by a sudden and marked
increase in systemic blood pressure (although normotensive
SRChasbeendescribed[15]),andacuterenalfailure,withor
without signiﬁcant microangiopathic hemolytic anemia or
thrombocytopenia. SRC is often accompanied by headache,
blurring of vision, and dyspnea. These symptoms can be
attributed to hypertensive encephalopathy, congestive heart
failure, and/or pulmonary edema, respectively, as conse-
quencesoftherapidincreaseinbloodpressure[16,17].Since
SRC can present as acute renal failure, one would expect a
signiﬁcant elevation of serum creatinine and a considerable
fall of glomerular ﬁltration rate (GFR). In a relatively large
study, the median serum creatinine value in SRC patients at
presentation was 200mmol/l (2.3mg/dl) [18]. In our study,
the median serum creatinine value at the time of biopsy was
362mmol/l (4.1mg/dl) [13].
SRC more frequently aﬀects females than males [1]. This
may reﬂect the overall increased prevalence of SSc in the
female population. Rapid progression of skin thickening
in patients with SSc [19] and high doses of corticos-
teroid therapy [20] are risk factors for the development
of SRC. The latter is usually associated with systemic
steroid administration [20]. However, rare cases of SRC
have been described following topical steroid use [21]. In
patients with SRC, presenting normal or mildly elevated
blood pressures (normotensive SRC), older age and male sex
have been suggested to be adverse prognostic factors [18].
The poor prognosis in normotensive SRC patients might
reﬂect ongoing subclinical renal injury leading to severe
irreversible destruction of renal parenchyma due to delayed
diagnosis.
Virtually all SRC patients have detectable antinuclear
antibodies (ANA). Anti-RNA polymerase antibodies (espe-
cially types I and III), which are the most frequent autoan-
tibodies encountered in North American dcSSc patients,
are signiﬁcantly associated with the development of SRC
[8, 9, 22]. An association with antitopoisomerase I (anti-
Scl 70) antibodies in dcSSc patients has also been reported.
In contrast, anticentromere antibodies, which are commonly
detected in lcSSc, are rarely encountered [19]. Anti-U3 RNP
antibodies were found to have an association with SRC in
some [23]b u tn o ta l l[ 24] studies.
Microangiopathic hemolytic anemia occurs in up to half
of SRC patients [25] and is characterized by abrupt onset
of anemia, the presence of schistocytes in the peripheral
blood smear, and thrombocytopenia. Thrombotic microan-
Figure 1: Arterial thrombosis associated with prominent glomeru-
lar ischemic collapse in a patient with scleroderma renal crisis
(Methenamine silver stain; original magniﬁcation x100).
giopathy is often accompanied by elevated serum LDH and
decreased haptoglobin.
3.GrossPathology
Multiple, small petechial hemorrhages are frequently present
on the surface of the aﬀected kidneys. The cut section may
reveal tiny wedge shaped infarcts and foci of cortical necrosis
[26]. These changes are nonspeciﬁc and can be observed
in other thrombotic microangiopathic disorders, such as
hemolytic uremic syndrome, thrombotic thrombocytopenic
purpura, and idiopathic malignant hypertension, or in
association with some medications.
4.Microscopic Pathology
Renal biopsies, even though necessary to conﬁrm the
diagnosis, are not routinely warranted in SRC. Theoretically,
unless the patient is suﬀering from typical clinical features
and is associated with thrombotic microangiopathy picture
on peripheral blood examination, the diagnosis cannot be
conﬁrmed with certainty without a renal biopsy. However,
renal biopsy is an invasive procedure. Practically, such
biopsies are recommended when doubt exists about the
etiology of renal dysfunction, or, alternatively, to exclude the
presence of other pathologic conditions.
The overall microscopic picture is that of a thrombotic
microangiopathic process [26, 27]. Similar to idiopathic
malignant hypertension, and in contrast to hemolytic ure-
mic syndrome and thrombotic thrombocytopenic purpura,
primary small vessel changes usually predominate over
glomerular alterations in SRC. Small vessel thrombi out-
numbered glomerular thrombi in SRC [11/17 (65%) versus
3/17 (18%), P = .01] [13], while the opposite was found in
hemolytic uremic syndrome; thrombotic microangiopathy
changes were more commonly detected in the glomeruli
compared to small vessels [11/12 (92%) versus 4/12 (33%),
P = .009] [28].International Journal of Rheumatology 3
Figure 2: Prominent arterial onion skin lesion in a patient with
scleroderma renal crisis. Such lesions often cause severe vascular
narrowingleavingonlyapinpointopenlumen(Methenaminesilver
stain; original magniﬁcation x400).
Figure 3: Glomerular capillary thrombosis in a patient with sclero-
derma renal crisis. This ﬁnding is rather infrequent in scleroderma
renal crisis and is more commonly observed in hemolytic uremic
anemia and thrombotic thrombocytopenic purpura (Methenamine
silver stain; original magniﬁcation x600).
Figure 4: Prominent juxtaglomerular apparatus containing sparse
silver positive renin granules in a patient with scleroderma renal
crisis (Methenamine silver stain; original magniﬁcation x400).
Figure 5: Electron microscopy from a patient with scleroderma
renal crisis reveals detachment of the endothelium and prominent
electron lucent ﬂuﬀy material (Electron microscopy; original
magniﬁcation x5600).
Histologic manifestations may vary during the course of
the disease. Early vascular changes can manifest as intimal
accumulation of myxoid material, thrombosis (Figure 1),
and/or ﬁbrinoid necrosis. Onion-skin lesions develop later
(Figure 2), while ﬁbrointimal sclerosis with or without
adventitial ﬁbrosis may be the only manifestation of chronic
ongoing damage or organization resulting from previous
episodes of acute injury. Acute glomerular changes can
occur primarily or often develop secondary to the vascular
injury and reduction in renal perfusion. Primary glomerular
changesappeartoberelatedtoglomerularendothelialinjury.
These can manifest as endothelial swelling and glomeru-
lar capillary thrombosis (Figure 3). The latter is relatively
infrequent [13]. Chronic glomerular changes, which include
basement membrane double contours (tram tracking) and
glomerulosclerosis, may develop later. Secondary glomerular
changes may result in ischemic glomerular collapse. JGA
hyperplasia,ahistologicsequelofincreasedreninproduction
can be observed microscopically (Figure 4). Prominent JGA
hyperplasia was found to be present in 2/17 (12%) of our
SRC cases [13]. Tubulointerstitial changes, which are also
secondary to vascular pathology, are frequently manifested
as ischemic acute tubular injury/necrosis or, if more chronic,
as tubular atrophy and interstitial ﬁbrosis. A lymphohistio-
cytic interstitial inﬂammatory inﬁltrate can occasionally be
observed.
Finally, even though SRC represents an acute form of
renal involvement, vascular pathology may be observed in
SScpatientsintheabsenceofSRC.Trostleetal.[14],inacase
control autopsy study, compared the intimal surface areas
of renal arteries in SSc autopsy cases (SRC, dcSSc without
SRC, and lcSSc without SRC) to age- and sex-matched
autopsy controls. Using morphometric techniques, these
investigators conﬁrmed that SRC patients had a signiﬁcant4 International Journal of Rheumatology
increase in renal arterial intimal thickening. Interestingly,
they also found that, in the absence of SRC, a signiﬁcant
increase in arterial ﬁbrointimal thickness was observed in
dcSSc patients, and to a lesser extent in lcSSc patients,
compared to controls. Such vascular changes may be due to
the presence of mild ongoing renal vascular injury below the
threshold which triggers SRC.
5.AncillaryStudies
Immunoﬂuorescence and electron microscopy are routinely
used ancillary studies for evaluating native renal biopsies.
Immunoﬂuorescence studies are mainly utilized to charac-
terize the presence, nature, pattern of staining, and anatomic
distribution of immune deposits. Electron microscopy is
used for ultrastructural assessment of renal biopsies. It is
extremely helpful in localizing and characterizing immune
complex and protein deposits with organized substructures
(amyloidosis, ﬁbrillary etc.) and to assess the glomerular
endothelium, basement membrane, and podocytes.
Routine ancillary studies are of limited value in con-
ﬁrming the diagnosis of SRC. There are only a few reports
which have characterized the immunoﬂuorescence ﬁndings
in SRC. Immunoglobulin deposits in the glomeruli and/or
blood vessels were identiﬁed in most but not all of these
studies. Among the immunoglobulin deposits, IgM, which
might be considered the result of a nonspeciﬁc entrapment,
was the most frequently detected [29–31]. This was often
accompanied by complement deposits.
In SRC, electron microscopic evaluation frequently fails
to detect discrete electron dense deposits. Hyaline material
often accumulates in the subendothelium of the glomeruli
and/or blood vessels in SRC [29–32]. Of note, hyaline
deposits can sometimes be diﬃcult to distinguish from
deﬁnite immune complex deposits. Evidence of endothelial
injury such as endothelial swelling and prominent accumu-
lation of glomerular subendothelial electron lucent material
have been described in SRC (Figure 5) but also in malignant
hypertension [33]. Myointimal cells were detected in the
extended ﬁbrointima in SRC patients [34].
C4d is a complement split product which is gen-
erated following complement activation via classical or
mannose-bound lectin pathways. C4d can be detected using
immunoperoxidase on formalin ﬁxed tissue or immunoﬂuo-
rescence on frozen tissue. The former is technically easier to
perform while the latter is considered slightly more sensitive
and speciﬁc. We identiﬁed ﬁnely granular C4d staining
in the peritubular capillary of a subset of SRC patients
who had associated poor renal outcome [13]. In allograft
kidneys, the detection of peritubular capillary C4d staining
is usually associated with antibody-mediated rejection and
poor allograft outcome [35–37]. Confocal immunoﬂuores-
cence can potentially play an important role in localizing
C4d as a target. Although a larger multicenter study using
immunoﬂuorescence technique is needed to validate our
preliminary ﬁndings and to further characterize the cause
of such deposits, evidence supporting the role of antibody-
mediated injury in SSc/SRC patients is accumulating. First,
Figure 6: Prominent arterial adventitial ﬁbrosis in a patient with
scleroderma renal crisis. Note that the arteries also have mild
intimal accumulation of myxoid material. (Methenamine silver
stain; original magniﬁcation x100).
disease-speciﬁc serum autoantibodies have been found to
be associated with certain clinical manifestations [22].
Second, antiendothelial antibodies and increased expression
of endothelin-1/endothelin-B have been detected in a subset
of SRC patients [12]; it is noteworthy that overexpression
of endothelin-1 gene has been recently discovered in allo-
graft kidneys with antibody-mediated rejection [38]. Lastly,
antiglobulin antibodies have been found in the eluate of
several SRC kidney samples [30].
6. DifferentialDiagnosis
Clinically, SRC should be suspected when acute renal failure
(ARF) develops in SSc patients. Nevertheless, ARF occurring
in SSc patients is not always due to SRC. Renal artery
stenosis, hypovolemia, crescentic glomerulonephritis (GN),
and other renal diseases may also occur in SSc patients [27].
These disorders may result in a similar clinical picture. A
thromboticmicroangiopathy-likeclinicalpicturecanevenbe
encountered in patients with renal arterial stenosis [27]. Dis-
tinguish SRC from crescentic GN is critical since immuno-
suppressive therapy is used to treat the latter. As the name
implies,thepresenceofcrescentsisthehallmarkofcrescentic
GN. In typical SRC cases, crescents are extremely rare and,
when detected, are very small [39]. In SSc patients, most
of the encountered crescentic GN are ANCA-associated.
These are pauci-immune on immunoﬂuorescence studies,
associatedwithanti-myeloperoxidaseantibodies,andusually
triggered by penicillamine [40, 41]. Less often, one may
encounter immune complex GN [39] or antiglomerular
basement membrane GN [42]. Immunoﬂuorescence studies
reveal granular glomerular basement membrane and/or
mesangial immune complex deposits in the former and
linear glomerular basement membrane IgG staining in the
latter.
Histologically,thromboticmicroangiopathicchangescan
be observed in several disorders. Although it is often
impossible to ascertain the speciﬁc cause of thrombotic
microangiopathy based on histologic evaluation alone, itInternational Journal of Rheumatology 5
(a) (b)
Figure 7: Two renal allograft biopsies with histologic features suspicious for recurrence of scleroderma. Note the prominent myxoid changes
in the artery in biopsy (a) as well as the severe intimal thickening of blood vessels, which is accompanied by thrombosis and schistocytes
within the arteriole wall in biopsy (b). The diﬀerential diagnosis includes acute antibody-mediated rejection and acute calcineurin inhibitor
toxicity. Clinical correlation with the presence of C4d stain, detection of circulating donor-speciﬁc antibodies, and calcineurin inhibitor
levels are usually warranted to achieve a correct diagnosis [(a) H&E; original magniﬁcation x200 and (b) Methenamine silver stain; original
magniﬁcation x400].
is important to note that extraglomerular small vessel
vascular lesions often predominate in SRC while primary
glomerular capillary microangiopathic changes (glomerular
capillary thrombosis) are a relatively infrequent histologic
ﬁnding in SRC [13]. The presence of JGA hyperplasia has
been described in SRC patients [43, 44]. Similarly, vascular
adventitial ﬁbrosis (Figure 6)[ 45] has been regarded by
some investigators to be characteristic for SSc [46]a n d
SRC [47]. Clinicopathological correlation, however, is often
required to achieve the correct diagnosis. In advanced stages
of SRC, the histologic ﬁndings are usually nonspeciﬁc and
reﬂect advanced chronic renal damage. At such late stages,
it is often diﬃcult to distinguish chronic vascular changes
associated with organized SRC from preexisting chronic
accelerated essential hypertension. The presence of peri-
adventitial ﬁbrosis, if prominent, might be helpful as a point
in favor of SRC.
7.Prognosis
Several retrospective studies have investigated the role of
renal biopsy in predicting prognosis in SRC. Penn et al.
showed that the presence of acute vascular changes (myxoid
intimal thickening and thrombosis) were associated with
poor prognosis [18]. We showed that the severity and extent
of acute vascular injury, including ﬁbrinoid changes and/or
thrombosis, was most predictive of poor outcome [13].
We also showed that severe glomerular ischemic collapse,
and to a lesser extent acute tubular necrosis, may also be
associated with poor prognosis [13]. Both of the latter are
secondary changes reﬂecting the severity of vascular lesions.
In contrast to acute changes, we observed that chronic renal
changes did not signiﬁcantly correlate with poor outcome
[13]. A recently published abstract suggested that chronic
pathological changes might be associated with a favorable
prognosis [48]. The latter observation is diﬃcult to explain
since chronic changes are typically irreversible and are
expected, if any, to have an adverse impact on renal survival,
as was described in other kidney diseases such as lupus
nephritis [49].
8. Treatment/Outcome
Blood pressure should be vigorously and aggressively con-
trolled in patients with established SRC. The mortality
associated with SRC has signiﬁcantly decreased due to early
diagnosis and aggressive angiotensin-converting enzyme
(ACE) inhibitor therapy [50, 51] .S t i l l ,as u b s e to fS R C
patientsmayberefractorytoACE-inhibitorandotherhyper-
tensivetherapy.Thesepatientsoftenremainondialysisordie
[17, 51, 52]. Kidney transplantation should be considered if
the condition does not reverse despite aggressive treatment
(usually within two years) [53].
9. PosttransplantOutcome
Although renal transplantation oﬀers superior survival in
SRC patients, graft survival is frequently reduced in SSc-
induced renal failure compared to the general renal trans-
plant population [54, 55]. We retrospectively studied the
posttransplantation course of 10 SRC patients [56]. One,
three, and ﬁve year graft survivals in this SRC cohort of
patients were 70%, 70%, and 25%, respectively, compared
with approximately 90%, 79%, and 75% graft survival in
miscellaneous patients who received kidney transplants from
deceased donors at the same institution [57]. Recurrence of
scleroderma (Figure 7) may play a role in this poor post-
renaltransplantoutcome[58,59].Twoofour10patientshad
histologicfeaturessuspiciousforSRCrecurrence,manifested
by both exacerbated development of arterial ﬁbrointimal6 International Journal of Rheumatology
thickening with thrombotic microangiopathy-like changes
[56]. Pham et al. [59] found that recurrent SRC occurs
early in the course of transplantation (within 2 years post-
transplantation). However, Cheung et al. [58] challenged the
conventional experience by reporting a recurrence of SRC
which occurred seven years post-transplantation. This SRC
occurred following switching therapy from an ACE inhibitor
to an angiotensin II receptor blocker.
Establishing a histologic diagnosis of recurrent sclero-
derma/SRC in an allograft is more challenging than diag-
nosing SRC in a native kidney biopsy. In addition to recur-
rent SRC, the pathologic diﬀerential diagnosis in allograft
biopsieswithathromboticmicroangiopathy-likepicturealso
includes antibody-mediated rejection, calcineurin inhibitor
toxicity, infection, and other less common allograft-related
abnormalities [60]. More chronic changes can also be diﬃ-
cult to distinguish from de novo transplant glomerulopathy.
In summary, SRC is a severe complication of systemic
sclerosis. Although not always clinically warranted, renal
biopsy can play an important role in establishing the
diagnosis and in excluding other pathologic conditions
such as vasculitis and connective tissue disease related
and nonrelated syndromes. Furthermore, renal biopsies can
help to predict renal prognosis and may contribute to our
better understanding of the mechanisms and pathologic
manifestations of SRC, ultimately leading to optimization of
treatment strategies.
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